文献速递浆细胞疾病造血干细胞移植与细胞治疗

BCMA与GPRC5D CAR T细胞同步输注治疗晚期多发性骨髓瘤的1期试验

Concurrent administration of BCMA and GPRC5D CAR T cells for advanced multiple myeloma.
PubMed 文献 · Blood · 2026-01-01

这项1期剂量递增试验评估了BCMA CAR T细胞MCARH125单用或与GPRC5D CAR T细胞MCARH109同步输注治疗复发/难治多发性骨髓瘤的安全性。共治疗15例患者(6例单用MCARH125,9例同步输注),同步输注总缓解率78%,中位无进展生存期18.2个月。未出现≥3级细胞因子释放综合征或免疫效应细胞相关神经综合征。

要点

  • 同步输注BCMA与GPRC5D CAR T细胞未出现≥3级CRS或ICANS。
  • 同步输注总缓解率78%,中位PFS 18.2个月。
  • 双抗原靶向时仍可能因抗原丢失耐药,且一种CAR扩增可能限制另一种。

核心结论

  • BCMA与GPRC5D CAR T细胞同步输注在复发/难治多发性骨髓瘤中安全性可控,未出现≥3级CRS或ICANS。
  • 同步输注总缓解率78%,中位无进展生存期18.2个月。
  • 即使双抗原靶向,抗原丢失仍可能是重要耐药机制。

研究设计与样本

  • 1期剂量递增试验,评估MCARH125单用或与MCARH109同步输注的安全性。
  • 共治疗15例复发/难治多发性骨髓瘤患者,3个剂量水平。
  • 6例接受MCARH125单用,9例接受MCARH125与MCARH109同步输注。
  • 试验注册号NCT05431608。

主要发现

  • MCARH125单用组和同步输注组各有1例发生免疫效应细胞相关噬血细胞综合征。
  • 未出现≥3级细胞因子释放综合征或免疫效应细胞相关神经综合征。
  • 同步输注总缓解率78%,中位无进展生存期18.2个月。
  • 同步输注患者BCMA CAR扩增显著低于MCARH125单用患者,尽管输注时BCMA CAR T细胞剂量相当。

关键数值与推荐

  • 同步输注总缓解率78%,中位无进展生存期18.2个月。

临床怎么用

  • BCMA与GPRC5D CAR T细胞同步输注可作为复发/难治多发性骨髓瘤的潜在治疗策略。
  • 需监测免疫效应细胞相关噬血细胞综合征。
  • 双抗原靶向仍需关注抗原丢失及CAR扩增相互限制。

局限性

  • 样本量小(共15例),为1期剂量递增试验。
  • 原文未报告随机对照或长期随访数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

B-cell maturation antigen (BCMA)- and G protein-coupled receptor class C group 5 member D (GPRC5D)-directed therapies have shown high efficacy in the treatment of relapsed or refractory multiple myeloma, with multiple new immune therapies now approved. Preclinical studies have shown that the expression of BCMA and GPRC5D is heterogeneous in malignant plasma cells. We conducted a phase 1 dose-escalation trial of the BCMA chimeric antigen receptor (CAR) T-cell therapy MCARH125 alone or in combination with the GPRC5D CAR T-cell therapy MCARH109 in patients with relapsed or refractory multiple myeloma. Patients were treated across 3 dose levels, with the primary objective of establishing the safety of concurrent infusion. We treated 15 patients across 3 dose levels, including 6 patients who received MCARH125 alone and 9 patients treated with the concurrent infusion of MCARH125 and MCARH109. One patient each with MCARH 125 alone and the coinfusion of MCARH125 and MCARH109 developed immune effector cell-associated hemophagocytic syndrome. There were no instances of grade ≥3 cytokine release syndrome or immune effector cell-associated neurologic syndrome. The overall response for coinfusion was 78%, with a median progression-free survival of 18.2 months. Correlative analysis suggests that antigen loss may be an important mechanism of resistance even with dual-antigen targeting, and we show, to our knowledge for the first time that expansion of 1 CAR population may limit expansion of the second population because patients treated with dual CARs had significantly less BCMA CAR expansion compared with patients treated with BCMA CAR alone, despite equivalent BCMA CAR T-cell doses at infusion. This trial was registered at www.clinicaltrials.gov as NCT05431608.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Mailankody S, Mitra S, Herrera K, et al. Concurrent administration of BCMA and GPRC5D CAR T cells for advanced multiple myeloma. Blood. 2026. PMID: 42413007. doi:10.1182/blood.2025032122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。